Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Regen BioPharma's Sloan Ratio for the quarter that ended in Mar. 2026 was 0.00%.
As of Mar. 2026, Regen BioPharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Regen BioPharma (OTCPK:RGBP) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Regen BioPharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Regen BioPharma Sloan Ratio % Related Terms
Regen BioPharma Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: Sloan Ratio % Comparison
For the Biotechnology subindustry, Regen BioPharma's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Regen BioPharma's Sloan Ratio for the fiscal year that ended in Sep. 2025 is calculated as
Regen BioPharma's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -0.167 (Jun. 2025 ) + -0.572 (Sep. 2025 ) + -0.968 (Dec. 2025 ) + 0.992 (Mar. 2026 ) = $-0.72 Mil.
Regen BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -0.056 (Jun. 2025 ) + -0.16 (Sep. 2025 ) + -0.198 (Dec. 2025 ) + -0.063 (Mar. 2026 ) = $-0.48 Mil.
Regen BioPharma's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was 0 (Jun. 2025 ) + 0 (Sep. 2025 ) + 0 (Dec. 2025 ) + 0 (Mar. 2026 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Sloan Ratio % of 0.00% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's Sloan Ratio % too high?
Regen BioPharma's current Sloan Ratio % is 0.00%.
How does Regen BioPharma's Sloan Ratio % compare to SIGY and ENDV?
Regen BioPharma's Sloan Ratio % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Sloan Ratio % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
